EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Eighteen‐Months Safety and Efficacy Following Intraperitoneal Treatment With 224 Radium‐Labeled Microparticles After CRS‐HIPEC in Patients With Peritoneal Metastasis From Colorectal Cancer

S G Larsen, W Graf, R H Larsen, M-E Revheim, A M Mariathasan, O Sørensen, M Spasojevic, G Rashid, N Lundstrøm, T J Gjertsen, A-K Aksnes, Ø S Bruland

Journal of Surgical Oncology · 2024

DOI: 10.1002/jso.27897 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of Surgical Oncology, 2024. Verfasst von S G Larsen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncological Surgery, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway. Hauptthemen laut MEDLINE: Peritoneal Neoplasms, Colorectal Neoplasms, Hyperthermic Intraperitoneal Chemotherapy, Cytoreduction Surgical Procedures. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: This study was supported by Oncoinvent A/S, N-0484 Oslo, Norway; Innovation Norway, Pb. 448, N-0104 Oslo, Norway..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives Peritoneal metastasis from colorectal cancer carries a high risk for relapse after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS‐HIPEC). A novel alpha‐emitting radiopharmaceutical (Radspherin) has been designed to deliver short‐range radiation to micrometastases and free‐floating tumor cells.

Methods

A Phase 1/2a study evaluated the safety, tolerability, and signal of efficacy of escalating doses of Radspherin injected intraperitoneally after CRS‐HIPEC.

Results

Eleven patients received 1−4 MBq (Group 1) whereas 12 patients received 7 MBq; nine patients single dose/three patients split‐dose (Group 2). Median age was 66.5 and 61.5 years, and median peritoneal cancer index 6 and 7, respectively. One hundred and seventy‐eight adverse events were reported, only seven were deemed related to Radspherin. Thirteen serious adverse events (SAEs) were reported in eight patients and no SAEs were related to Radspherin. At 18‐months, none of the 12 patients receiving 7 MBq experienced peritoneal recurrences, however four had non‐peritoneal recurrences. Across both groups ( n = 22), 41% had recurrent disease, only 14% of them in the peritoneum.

Conclusions

Radspherin was well tolerated. At 18 months, median disease‐free survival has not been reached, and none of the patients receiving the recommended dose (7 MBq) had peritoneal recurrences. The results are encouraging and warrant further clinical evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peritoneal NeoplasmsColorectal NeoplasmsHyperthermic Intraperitoneal ChemotherapyCytoreduction Surgical ProceduresRadiopharmaceuticalsHumansMiddle AgedAgedMaleFemaleCombined Modality TherapyNeoplasm Recurrence, Local

Stichwörter der Autor:innen

alpha‐emitterclinical trialscytoreductive surgery (CRS)hyperthermic intraperitoneal chemotherapy (HIPEC)peritoneal metastasisradiopharmaceutical

Substanzen

Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Oncological Surgery, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
  • Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
  • Department of Surgery, Uppsala Academic Hospital, Uppsala, Sweden.
  • Sciencons A/S, Oslo, Norway.
  • Faculty of Medicine, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.
  • The Intervention Centre, Oslo University Hospital, Oslo, Norway.

Förderung

  • This study was supported by Oncoinvent A/S, N-0484 Oslo, Norway; Innovation Norway, Pb. 448, N-0104 Oslo, Norway.

Zitieren

APA

Larsen, S. G., Graf, W., Larsen, R. H., Revheim, M. E., Mariathasan, A. M., Sørensen, O., Spasojevic, M., Rashid, G., Lundstrøm, N., Gjertsen, T. J., Aksnes, A. K., & Bruland, Ø. S. (2024). Eighteen‐Months Safety and Efficacy Following Intraperitoneal Treatment With 224 Radium‐Labeled Microparticles After CRS‐HIPEC in Patients With Peritoneal Metastasis From Colorectal Cancer. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27897

Vancouver

Larsen SG, Graf W, Larsen RH, Revheim ME, Mariathasan AM, Sørensen O, et al. Eighteen‐Months Safety and Efficacy Following Intraperitoneal Treatment With 224 Radium‐Labeled Microparticles After CRS‐HIPEC in Patients With Peritoneal Metastasis From Colorectal Cancer. Journal of Surgical Oncology. 2024. doi:10.1002/jso.27897

BibTeX
@article{Larsen2024,
  author = {Larsen, S G and Graf, W and Larsen, R H and Revheim, M-E and Mariathasan, A M and Sørensen, O and Spasojevic, M and Rashid, G and Lundstrøm, N and Gjertsen, T J and Aksnes, A-K and Bruland, Ø S},
  title = {Eighteen‐Months Safety and Efficacy Following Intraperitoneal Treatment With 224 Radium‐Labeled Microparticles After CRS‐HIPEC in Patients With Peritoneal Metastasis From Colorectal Cancer},
  journal = {Journal of Surgical Oncology},
  year = {2024},
  doi = {10.1002/jso.27897}
}
Kostenlos starten →